phenpropamine

Small moleculeexperimental

Alverine is a smooth muscle relaxant used for the treatment irritable bowel syndrome. Alverine may increase calcium influx during action potentials due to inhibition of the inactivation of L-type calcium channels, but may also suppress evoked activity by inhibiting the sensitivity of contractile proteins to calcium. — NCATS

Clinical trial activity

3 trials · 2 clinical orgs · 0 marketing orgs

Phase 1

Phase 2

Phase 3

Phase 4

Earliest trial started Jul 1, 2007 (NCT00542295)

Timeline

2020s

Jan 1, 2022
Earliest Phase 2 Sponsor(trial)

Indications

Approved for

Irritable Bowel Syndrome

Studied for

Mechanism of action

Hepatocyte nuclear factor 4-alphaACTIVATOR
HNF4A activator
Alverine has been shown to bind to 5-HT1A receptors thereby acting as an antagonist that reduces the visceral pronociceptive effect of 5-HT. Alverine acts directly on the muscle in the gut, causing it to relax. This prevents the muscle spasms which occur in the gut in conditions such as irritable bowel syndrome and diverticular disease. It has also been reported that Alverine acts as HNF4¿ activator.
- Hepatocyte nuclear factor 4-alpha (HNF4A) ↗
Serotonin 1a (5-HT1a) receptorANTAGONIST
HTR1A antagonist
Alverine has been shown to bind to 5-HT1A receptors thereby acting as an antagonist that reduces the visceral pronociceptive effect of 5-HT. Alverine acts directly on the muscle in the gut, causing it to relax. This prevents the muscle spasms which occur in the gut in conditions such as irritable bowel syndrome and diverticular disease. It has also been reported that Alverine acts as HNF4¿ activator.
- 5-hydroxytryptamine receptor 1A (HTR1A) ↗

Chemistry & pharmacology

Loading structure…

SMILES

CCN(CCCc1ccccc1)CCCc1ccccc1

Mol. weight: 281.44 g/mol
Lipinski Ro5: Pass
Rule of 3: No
Chirality: Achiral Molecule
Inorganic: No
Polymer: No

Oral

Parenteral

Topical

Sources

Also known as

alverina
alverina
alverine
alverine
alverine
alverine
alverine
alverine
alverine citrate
alverine citrate
alverine citrate
alverine citrate
alverine citrate
alverine citrate salt
alverine hydrochloride
alverine hydrochloride
alverine hydrochloride
alverine hydrochloride
alverine hydrochloride
alverine hydrochloride
alverinum
alverinum
audmonal
bis(gamma-phenylpropyl)ethylamine
bis(gamma-phenylpropyl)ethylamine
di(phenylpropyl)ethylamine
di(phenylpropyl)ethylamine
dipropylin
dipropyline
gielism
n-ethyl-3,3'-diphenyldipropylamine
n-ethyl-3,3'-diphenyldipropylamine
n-ethyl-3-phenyl-n-(3-phenylpropyl)-1-propanamine
n-ethyl-3-phenyl-n-(3-phenylpropyl)-1-propanamine
n-ethyl-n-(3-phenylpropyl)benzenepropanamine
n-ethyl-n-(3-phenylpropyl)benzenepropanamine
n,n-bis(3-phenylpropyl)ethylamine
n,n-bis(3-phenylpropyl)ethylamine
n,n-bis(3-phenylpropyl)ethylamine
norgine brand of alverine citrate
phenopropamine
phenopropamine
phenopropamine
phenpropamine
phenpropamine
phenpropamine
phenpropamine citrate
phenpropamine citrate
relaxyl
relaxyl
spasmaverine
spasmonal
spasmonal
spasmonal
spasmonal fte
united drug brand of alverine citrate

Clinical trials

NCT ID	Phase	Start date	Sponsor(s)
NCT05508633	Phase 2	Aug 31, 2022	Second Military Medical University
NCT01404923	Phase 4	Dec 1, 2009	Laboratoires Mayoly Spindler
NCT00542295	Phase 4	Jul 1, 2007	Laboratoires Mayoly Spindler

Showing 3 of 3 trials

Page 1 / 1

Organizations

Research & Development (2)

Organization	Org type	Trials	As lead sponsor	Phases	Earliest year
Laboratoires Mayoly Spindler	For profit	2	2	1	2007
Second Military Medical University	Government	1	1	1	2022

2 organizations

Page 1 / 1